CVS Health shares tumbled 7.3% in pre-market trading on Wednesday, reversing earlier gains after the company's conference call revealed concerning forward-looking commentary that overshadowed a strong second-quarter earnings beat.

The healthcare giant initially rose as much as 5% after reporting adjusted earnings of $2.58 per share, well above the $1.85 consensus estimate, and raising its full-year adjusted EPS guidance to $7.90-$8.10 from $7.30-$7.50. However, the stock reversed course sharply during the conference call as executives flagged several headwinds. The company said it expects membership declines in its Caremark pharmacy benefits business next year, and warned that 340B market pressures will weigh on its pharmacy services business in 2027. CVS also maintained a cautious view for the remainder of the year, citing continued elevated cost trends and the potential for a difficult macroeconomic environment.

The negative forward-looking statements dampened enthusiasm from the otherwise robust quarterly results, which included a better-than-expected medical loss ratio of 87.4% in its Aetna insurance unit and the announcement of a new GLP-1 weight-loss drug partnership with Eli Lilly.